<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Aminocaproic acid: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Aminocaproic acid: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Aminocaproic acid: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="11582" href="/d/html/11582.html" rel="external">see "Aminocaproic acid: Patient drug information"</a> and <a class="drug drug_pediatric" data-topicid="12564" href="/d/html/12564.html" rel="external">see "Aminocaproic acid: Pediatric drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F133225"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Amicar [DSC]</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F133261"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Antifibrinolytic Agent;</li>
<li>
                        Antihemophilic Agent;</li>
<li>
                        Hemostatic Agent;</li>
<li>
                        Lysine Analog</li></ul></div>
<div class="block doa drugH1Div" id="F133228"><span class="drugH1">Dosing: Adult</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="c2e58b13-fe48-4ea1-95c6-b98b51a5d8cf">Acute bleeding</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Acute bleeding:</b>
<b>Oral, IV:</b> Loading dose: 4 to 5 g during the first hour, followed by 1 g/hour for 8 hours (or 1.25 g/hour using oral solution) or until bleeding is controlled; maximum daily dose: 30 g.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="69119195-e2f5-490e-98e4-d7bc22dcde14">Extracorporeal membrane oxygenation, refractory bleeding</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Extracorporeal membrane oxygenation, refractory bleeding (off-label use): IV:</b> Loading dose of 4 to 5 g; followed by an infusion of 1 to 1.25 g/hour until bleeding is controlled (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26907195']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26907195'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="31f50c43-e207-4171-a2ac-9501ea0c64be">Intracranial hemorrhage associated with thrombolytic treatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Intracranial hemorrhage associated with thrombolytic treatment (alternative therapy) (off-label use): </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Consider for use in addition to cryoprecipitate or when cryoprecipitate is contraindicated in patients who have a symptomatic intracranial hemorrhage after receiving thrombolytic within the past 24 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29367334','lexi-content-ref-26714677']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29367334','lexi-content-ref-26714677'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV:</b> Loading dose: 4 to 5 g, followed by 1 g/hour for 8 hours until bleeding is controlled (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29367334','lexi-content-ref-26714677','lexi-content-ref-29097489']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29367334','lexi-content-ref-26714677','lexi-content-ref-29097489'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="a9072a61-30f1-45d6-a2e3-5a4fb4bc8f6a">Mouth and mucosal bleeding in patients with hemostatic defects</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Mouth and mucosal bleeding in patients with hemostatic defects (eg, hemophilia, von Willebrand disease, other factor deficiencies associated with bleeding) (adjunctive therapy):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Generally, use in conjunction with (and not as a substitute for) replacement of the appropriate clotting factor, especially in individuals with hemophilia. Do not give simultaneously with an activated prothrombin complex concentrate, as this can increase the risk of thromboembolism; if used concurrently, they should be separated by ≥12 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22776238']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22776238'])">Ref</a></span>). Consultation with a hemophilia treatment center is advised.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> 50 to 100 mg/kg every 6 hours until wound has healed (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-NHF.2020']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-NHF.2020'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="6b934396-5e00-4bd1-a847-4edce2ad5dce">Perioperative prevention of blood loss and transfusion</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Perioperative prevention of blood loss and transfusion (eg, cardiac surgery, other surgeries with significant blood loss) (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Dosing and timing of administration varies widely; use is procedure and institution specific. Recommendations provided below are usual dosage ranges from a variety of surgeries; refer to institutional protocols for details on specific surgeries.</p>
<p style="text-indent:-2em;margin-left:4em;">Usual dose and range: <b>IV:</b> Loading dose of 5 to 10 g (or 75 to 150 mg/<b>kg</b>), followed by 1 g/hour (or 10 to 15 mg/<b>kg</b>/hour) until the end of the procedure or up to 8 hours after the procedure (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19730217','lexi-content-ref-Gravlee.1','lexi-content-ref-27671279','lexi-content-ref-31929250']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19730217','lexi-content-ref-Gravlee.1','lexi-content-ref-27671279','lexi-content-ref-31929250'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="e1ec6782-8b85-44b6-986c-2324d2e2fc4c">Thrombocytopenia, bleeding</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Thrombocytopenia (severe), bleeding (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">Loading dose: <b>IV:</b> 100 mg/kg (maximum dose: 5 g) over 30 to 60 minutes, followed by 1 g/hour; maximum daily dose: 24 g (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-2774776','lexi-content-ref-6965311']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-2774776','lexi-content-ref-6965311'])">Ref</a></span>). When bleeding has ceased, may consider transitioning to maintenance dose.</p>
<p style="text-indent:-2em;margin-left:4em;">Maintenance: <b>Oral, IV:</b> 1 to 4 g every 4 to 12 hours; maximum daily dose: 24 g; duration of therapy varies depending on etiology and patient factors, but may continue maintenance dose until platelet count is stable without the need for transfusions and the risk of bleeding is minimized (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23921838','lexi-content-ref-2774776','lexi-content-ref-6965311','lexi-content-ref-25641349']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23921838','lexi-content-ref-2774776','lexi-content-ref-6965311','lexi-content-ref-25641349'])">Ref</a></span>).</p></div>
</div>
</div>
<div class="block dora drugH1Div" id="F50992093"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">May accumulate in patients with decreased renal function. When used during cardiopulmonary bypass in anephric patients, a normal or slightly reduced loading dose and a continuous infusion rate of 5 mg/kg/hour has been recommended (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Gravlee.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Gravlee.1'])">Ref</a></span>).</p></div>
<div class="block doha drugH1Div" id="F50989315"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">No dosage adjustment provided in the manufacturer's labeling.</p></div>
<div class="block doe drugH1Div" id="F133229"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block dop drugH1Div" id="F133246"><span class="drugH1">Dosing: Pediatric</span><p>(For additional information <a class="drug drug_pediatric" data-topicid="12564" href="/d/html/12564.html" rel="external">see "Aminocaproic acid: Pediatric drug information"</a>)</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="3e7b6d7d-e215-47bc-8b5d-32485a676f7b">Hematuria, refractory</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hematuria (gross; upper tract), refractory:</b> Limited data available: Children ≥11 years and Adolescents: Oral: 100 mg/kg/dose every 6 hours; continue for 2 days beyond resolution of hematuria; dosing based on case series (n=4) which showed hematuria resolution within 2 to 7 days; risks and benefits must be weighed prior to use (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20650477']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20650477'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="76542db9-e806-4bd7-a47d-a31826666a2f">Hemorrhage in patients with hemostatic disorders, adjunct treatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hemorrhage (oral, epistaxis, menorrhagia) in patients with hemostatic disorders, adjunct treatment:</b> Limited data available: Infants, Children, and Adolescents: Oral: 50 to 100 mg/kg/dose every 6 hours; maximum daily dose: 24 <b>g/day</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Acharya.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Acharya.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="3d08e092-3362-472c-9cdf-925865658bdf">Mucosal bleeding in thrombocytopenia/platelet dysfunction, treatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Mucosal bleeding in thrombocytopenia/platelet dysfunction, treatment:</b> Limited data available: Infants, Children, and Adolescents: Oral, IV: 50 to 100 mg/kg/dose every 6 hours; maximum daily dose: 24 <b>g/day</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Bussel.1','lexi-content-ref-Lipton.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Bussel.1','lexi-content-ref-Lipton.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="149cd070-2b0d-4f1a-b486-5ed812d1d740">Prevention of bleeding associated with dental procedures in hemophilic patients</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Prevention of bleeding associated with dental procedures in hemophilic patients:</b> Limited data available: Infants, Children, and Adolescents: Oral: 50 to 100 mg/kg/dose every 6 hours; maximum daily dose: 24 <b>g/day</b>; used in conjunction with DDAVP or factor replacement therapy; continue for up to 7 days or until mucosal healing is complete (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Acharya.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Acharya.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="4b814f9e-4d76-49e5-a358-b38a289f9946">Prevention of bleeding associated with extracorporeal membrane oxygenation, high-bleeding risk patients</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Prevention of bleeding associated with extracorporeal membrane oxygenation (ECMO), high-bleeding risk patients:</b> Limited data available: Infants, Children, and Adolescents: IV: 100 mg/kg prior to or immediately after cannulation, followed by a continuous IV infusion of 25 to 30 mg/kg/hour for up to 72 hours; target activated clotting time (ACT) range during therapy of 180 to 200 seconds has been used (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12891495','lexi-content-ref-9856877','lexi-content-ref-8483066']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12891495','lexi-content-ref-9856877','lexi-content-ref-8483066'])">Ref</a></span>); variable results; patients requiring surgery just prior to or while on ECMO seem to benefit most.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="5de15ff9-1d3a-4e9d-be92-10e430fa73fd">Prevention of perioperative bleeding</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Prevention of perioperative bleeding:</b> Limited data available:</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Cardiac surgery with cardiopulmonary bypass:</i></p>
<p style="text-indent:-2em;margin-left:6em;">Infants and Children &lt;2 years: Dosing regimens variable: IV: In the largest trial (n=120, all patients &lt;20 kg), a dose of 75 mg/kg was administered at the beginning and end of cardiopulmonary bypass (CPB), and 75 mg/100 mL was added to the CPB priming fluid (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21115357']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21115357'])">Ref</a></span>). Another study group in 2 separate trials (n=110, age range: 2 months to 14 years) used a 100 mg/kg dose after induction, during CPB pump priming, and when weaning CPB (over 3 hours) for a total of 3 doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11081890','lexi-content-ref-15073700']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11081890','lexi-content-ref-15073700'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Children ≥2 years and Adolescents: IV: 100 mg/kg after induction, during CPB pump priming, and when weaning CPB (over 3 hours) for a total of 3 doses; regimen used in 2 separate trials (n=110, age range: 2 months to 14 years) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11081890','lexi-content-ref-15073700']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11081890','lexi-content-ref-15073700'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Craniofacial reconstruction surgery:</i></p>
<p style="text-indent:-2em;margin-left:6em;">Infants ≥6 months to Children ≤2 years: IV: 100 mg/kg administered over 10 minutes, followed by a continuous IV infusion of 40 mg/kg/hour until the end of surgery (ie, completion of skin closure). Dosing based on an open-label, non-randomized, dose escalation, population pharmacokinetic trial (n=18, median age: 39 weeks) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23353035']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23353035'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Spinal surgery (eg, idiopathic scoliosis)</i>
<i>:</i></p>
<p style="text-indent:-2em;margin-left:6em;">Children ≥11 years and Adolescents: IV: 100 mg/kg (maximum dose: 5 <b>g</b>) administered over 15 to 30 minutes after induction, followed by a continuous IV infusion of 10 mg/kg/hour for the remainder of the surgery; discontinued at time of wound closure (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11413428','lexi-content-ref-14752343','lexi-content-ref-27927417']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11413428','lexi-content-ref-14752343','lexi-content-ref-27927417'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="a4436abb-6c91-43c5-bf58-aaf16bc679f2">Traumatic hyphema</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Traumatic hyphema:</b> Limited data available: Infants, Children, and Adolescents: Oral: 50 to 100 mg/kg/dose every 4 hours for 5 days; maximum daily dose: 30 <b>g/day</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11732035','lexi-content-ref-10505828','lexi-content-ref-9098257']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11732035','lexi-content-ref-10505828','lexi-content-ref-9098257'])">Ref</a></span>).</p></div>
</div>
</div>
<div class="block dorp drugH1Div" id="F51064755"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments are provided in the manufacturer's labeling; aminocaproic acid may accumulate in patients with decreased renal function; use with caution.</p></div>
<div class="block dohp drugH1Div" id="F51064756"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments are provided in the manufacturer's labeling.</p></div>
<div class="block adr drugH1Div" id="F133193"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Frequency not defined.</p>
<p style="text-indent:-2em;margin-left:2em;">Cardiovascular: Arrhythmia, bradycardia, edema, hypotension, intracranial hypertension, peripheral ischemia, syncope, thrombosis</p>
<p style="text-indent:-2em;margin-left:2em;">Central nervous system: Confusion, delirium, dizziness, fatigue, hallucinations, headache, malaise, seizure, stroke</p>
<p style="text-indent:-2em;margin-left:2em;">Dermatologic: Rash, pruritus</p>
<p style="text-indent:-2em;margin-left:2em;">Gastrointestinal: Abdominal pain, anorexia, cramps, diarrhea, GI irritation, nausea, vomiting</p>
<p style="text-indent:-2em;margin-left:2em;">Genitourinary: Dry ejaculation</p>
<p style="text-indent:-2em;margin-left:2em;">Hematologic: Agranulocytosis, bleeding time increased, leukopenia, thrombocytopenia</p>
<p style="text-indent:-2em;margin-left:2em;">Local: Injection site necrosis, injection site pain, injection site reactions</p>
<p style="text-indent:-2em;margin-left:2em;">Neuromuscular &amp; skeletal: CPK increased, myalgia, myositis, myopathy, rhabdomyolysis (rare), weakness</p>
<p style="text-indent:-2em;margin-left:2em;">Ophthalmic: Vision decreased, watery eyes</p>
<p style="text-indent:-2em;margin-left:2em;">Otic: Tinnitus</p>
<p style="text-indent:-2em;margin-left:2em;">Renal: BUN increased, intrarenal obstruction (glomerular capillary thrombosis), myoglobinuria (rare), renal failure (rare)</p>
<p style="text-indent:-2em;margin-left:2em;">Respiratory: Dyspnea, nasal congestion, pulmonary embolism</p>
<p style="text-indent:-2em;margin-left:2em;">Miscellaneous: Allergic reaction, anaphylactoid reaction, anaphylaxis</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing and/or case reports: Hepatic lesion, hyperkalemia, myocardial lesion</p></div>
<div class="block coi drugH1Div" id="F133208"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">Disseminated intravascular coagulation (without heparin); evidence of an active intravascular clotting process.</p></div>
<div class="block war drugH1Div" id="F133190"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Intrarenal obstruction: May occur secondary to glomerular capillary thrombosis or clots in the renal pelvis and ureters; do not use in hematuria of upper urinary tract origin unless possible benefits outweigh risks.</p>
<p style="text-indent:-2em;margin-left:4em;">• Skeletal muscle weakness: Ranging from mild myalgias and fatigue to severe myopathy with rhabdomyolysis and acute renal failure has been reported with prolonged use. Monitor CPK; discontinue treatment with a rise in CPK.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Renal impairment: Use with caution in patients with renal impairment; may accumulate.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concurrent drug therapy issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Blood products: Do not administer with factor IX complex concentrates or anti-inhibitor coagulant complexes; may increase risk for thrombosis.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Dosage form specific issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Benzyl alcohol and derivatives: Some dosage forms may contain benzyl alcohol; large amounts of benzyl alcohol (≥99 mg/kg/day) have been associated with a potentially fatal toxicity (“gasping syndrome”) in neonates; the “gasping syndrome” consists of metabolic acidosis, respiratory distress, gasping respirations, CNS dysfunction (including convulsions, intracranial hemorrhage), hypotension and cardiovascular collapse (AAP ["Inactive" 1997]; CDC, 1982); some data suggests that benzoate displaces bilirubin from protein binding sites (Ahlfors, 2001); avoid or use dosage forms containing benzyl alcohol with caution in neonates. See manufacturer’s labeling.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Appropriate use: Do not administer without a definite diagnosis of laboratory findings indicative of hyperfibrinolysis. Inhibition of fibrinolysis may promote clotting or thrombosis; more likely due to the presence of disseminated intravascular coagulation.</p>
<p style="text-indent:-2em;margin-left:4em;">• IV administration: Avoid rapid IV administration; may induce hypotension, bradycardia, or arrhythmia; rapid injection of undiluted solution is not recommended.</p></div>
<div class="block foc drugH1Div" id="F133202"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intravenous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 250 mg/mL (20 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Amicar: 25% (236.5 mL [DSC]) [contains edetate (edta) disodium, methylparaben, propylparaben, saccharin sodium; raspberry flavor]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 25% (236.5 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Amicar: 500 mg [DSC], 1000 mg [DSC] [scored]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 500 mg, 1000 mg</p></div>
<div class="block geq drugH1Div" id="F133186"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F133210"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Aminocaproic Acid Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">250 mg/mL (per mL): $0.33 - $0.54</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Aminocaproic Acid Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.25 g/mL (per mL): $13.47</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Aminocaproic Acid Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">500 mg (per each): $7.16 - $31.84</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1000 mg (per each): $13.55 - $43.98</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block adm drugH1Div" id="F133205"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">Rapid IV injection (IVP) of undiluted solution is not recommended due to possible hypotension, bradycardia, and arrhythmia.</p>
<p style="text-indent:-2em;margin-left:2em;">IV: May administer loading dose over 15-60 minutes depending on indication; a continuous infusion may be necessary.</p></div>
<div class="block admp drugH1Div" id="F52612218"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">Oral: May administer without regard to food.</p>
<p style="text-indent:-2em;margin-left:2em;">Parenteral: Do not administer undiluted; rapid IV injection (IVP) of undiluted solution is not recommended due to possible hypotension, bradycardia, and arrhythmia.</p>
<p style="text-indent:-2em;margin-left:4em;">Intermittent IV infusion: After further dilution, administer over 10 to 60 minutes (rate dependent upon use) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11413428','lexi-content-ref-14752343','lexi-content-ref-27927417','lexi-content-ref-23353035','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11413428','lexi-content-ref-14752343','lexi-content-ref-27927417','lexi-content-ref-23353035','lexi-content-ref-Manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Continuous IV infusion: Must further dilute prior to administration.</p></div>
<div class="block uica drugH1Div" id="F14471315"><span class="drugH1">Usual Infusion Concentrations: Adult</span>
<p style="text-indent:0em;display:inline">
<b>IV infusion:</b> 5000 mg in 250 mL (concentration: 20 mg/mL) of D5W, NS, or Ringer's injection</p></div>
<div class="block use drugH1Div" id="F133204"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:0em;display:inline">
<b>Active bleeding:</b> To enhance hemostasis when fibrinolysis contributes to bleeding (causes may include cardiac surgery, hematologic disorders, neoplastic disorders, abruptio placentae, hepatic cirrhosis, and urinary fibrinolysis).</p></div>
<div class="block off-label drugH1Div" id="F25720677"><span class="drugH1">Use: Off-Label: Adult</span><p>Extracorporeal membrane oxygenation, refractory bleeding; Intracranial hemorrhage associated with thrombolytic treatment (alternative therapy); Mouth and mucosal bleeding in patients with hemostatic defects (eg, hemophilia, von Willebrand disease, other factor deficiencies associated with bleeding) (adjunctive therapy); Perioperative prevention of blood loss and transfusion (eg, cardiac surgery, other surgeries with significant blood loss); Thrombocytopenia (severe), bleeding</p></div>
<div class="block mst drugH1Div" id="F133270"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues: </span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Amicar may be confused with amikacin, Amikin</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">International issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Amicar [US] may be confused with Omacor brand name for Omega-3-Acid Ethyl Esters [multiple international markets]</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F13298735"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F133195"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Anti-inhibitor Coagulant Complex (Human): Antifibrinolytic Agents may enhance the thrombogenic effect of Anti-inhibitor Coagulant Complex (Human). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Factor IX Complex (Human) [(Factors II, IX, X)]: Antifibrinolytic Agents may enhance the adverse/toxic effect of Factor IX Complex (Human) [(Factors II, IX, X)]. Specifically, the risk for thrombosis may be increased. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Prothrombin Complex Concentrate (Human) [(Factors II, VII, IX, X), Protein C, and Protein S]: Antifibrinolytic Agents may enhance the adverse/toxic effect of Prothrombin Complex Concentrate (Human) [(Factors II, VII, IX, X), Protein C, and Protein S]. Specifically, the risk for thrombosis may be increased. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tretinoin (Systemic): May enhance the thrombogenic effect of Antifibrinolytic Agents. Management: Concomitant use of antifibrinolytics and tretinoin is not recommended. If combined, monitor patients closely for any signs of thrombotic complications.<i> Risk D: Consider therapy modification</i></p></div>
<div class="block pri drugH1Div" id="F133211"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;display:inline">Animal reproduction studies have not been conducted.</p></div>
<div class="block brc drugH1Div" id="F20520941"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:0em;display:inline">It is not known if aminocaproic acid is excreted in breast milk. The manufacturer recommends that caution be exercised when administering aminocaproic acid  to nursing women</p></div>
<div class="block mop drugH1Div" id="F133200"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Fibrinogen, fibrin split products, creatine phosphokinase (with long-term therapy), BUN, creatinine</p></div>
<div class="block pha drugH1Div" id="F133189"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Binds competitively to plasminogen; blocking the binding of plasminogen to fibrin and the subsequent conversion to plasmin, resulting in inhibition of fibrin degradation (fibrinolysis).</p></div>
<div class="block phk drugH1Div" id="F133207"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Onset of action: ~1 to 72 hours </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Distribution: Widely through intravascular and extravascular compartments; V<sub>d</sub>: Oral: 23 L;  IV: 30 L</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Metabolism: Minimally hepatic </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Bioavailability: Oral: 100% </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Half-life elimination: 1 to 2 hours </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Time to peak: Oral: 1.2 ± 0.45 hours </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Excretion: Urine (65% as unchanged drug, 11% as metabolite)</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F6038523"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Ipsilon</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Amicar</span>;</li>
<li>
<span class="countryCode">(BD)</span> <span class="country">Bangladesh</span><span class="countrySeparator">: </span><span class="drugName">Hemolysin</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Ipsilon</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Eac</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Acidum aminocaproicum | Acidum aminocapronicum</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Epsikapron | Epsilon</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Hamostat</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Caprolisin</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Hemotin | Ipsilon | Resplamin | Roan</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Amicap | Capronin | Minosilon-s</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Acidum aminocapronicum</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Acidum aminocapronicum</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Amicar</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Amicar</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Amicar</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Epsicaprom</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Acidum aminocapr | Acidum aminocapronicum | Aminocaproic acid Solopharm | Aminocapronic acid | Aminokapronovaya kislota</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Epsikapron</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Hemocaprol</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Ipron | Plaslloid | Resplamin</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Acidum aminocapronicum | Aminocapronic acid</span>;</li>
<li>
<span class="countryCode">(UG)</span> <span class="country">Uganda</span><span class="countrySeparator">: </span><span class="drugName">Aminocaproic acid uf</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Amicar</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-Acharya.1">
<a name="Acharya.1"></a>Acharya S, "Hemostatic Disorders," <i>Manual of Pediatric Hematology and Oncology</i>, 5th ed, Lanzkowsky P, ed, Burlington, MA: Academic Press, 2011, 402-3.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11487763">
<a name="11487763"></a>Ahlfors CE. Benzyl alcohol, kernicterus, and unbound bilirubin. <i>J Pediatr</i>. 2001;139(2):317-319.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aminocaproic-acid-drug-information/abstract-text/11487763/pubmed" id="11487763" target="_blank">11487763</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Amicar.1">
<a name="Amicar.1"></a>Amicar (aminocaproic acid) oral solution and tablets [prescribing information]. Atlanta, GA: Mikart LLC; March 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Civica.1">
<a name="Civica.1"></a>Aminocaproic acid injection solution [prescribing information]. Lehi, UT: Civica, Inc; May 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-AmericanRegent.1">
<a name="AmericanRegent.1"></a>Aminocaproic acid injection solution [prescribing information]. Shirley, NY: American Regent, Inc; May 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23921838">
<a name="23921838"></a>Antun AG, Gleason S, Arellano M, et al. Epsilon aminocaproic acid prevents bleeding in severely thrombocytopenic patients with hematological malignancies. <i>Cancer</i>. 2013;119(21):3784-3787. doi:10.1002/cncr.28253<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aminocaproic-acid-drug-information/abstract-text/23921838/pubmed" id="23921838" target="_blank">23921838</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22050802">
<a name="22050802"></a>Banerjee A, Stoica C, and Walia A, "Acute Hyperkalemia as a Complication of Intravenous Therapy With Epsilon-Aminocaproic Acid," <i>J Clin Anesth</i>, 2011, 23(7):565-8.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aminocaproic-acid-drug-information/abstract-text/22050802/pubmed" id="22050802" target="_blank">22050802</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2774776">
<a name="2774776"></a>Bartholomew JR, Salgia R, and Bell WR, “Control of Bleeding in Patients With Immune and Nonimmune Thrombocytopenia With Aminocaproic Acid,” <i>Arch Intern Med</i>, 1989, 149(9):1959-61.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aminocaproic-acid-drug-information/abstract-text/2774776/pubmed" id="2774776" target="_blank">2774776</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19730217">
<a name="19730217"></a>Berenholtz SM, Pham JC, Garrett-Mayer E, et al. Effect of epsilon aminocaproic acid on red-cell transfusion requirements in major spinal surgery. <i>Spine (Phila Pa 1976)</i>. 2009;34(19):2096-2103. doi:10.1097/BRS.0b013e3181b1fab2<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aminocaproic-acid-drug-information/abstract-text/19730217/pubmed" id="19730217" target="_blank">19730217</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11732035">
<a name="11732035"></a>Brandt MT and Haug RH, "Traumatic Hyphema: A Comprehensive Review," <i>J Oral Maxillofac Surg</i>, 2001, 59(12):1462-70.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aminocaproic-acid-drug-information/abstract-text/11732035/pubmed" id="11732035" target="_blank">11732035</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26907195">
<a name="26907195"></a>Buckley LF, Reardon DP, Camp PC, et al. Aminocaproic acid for the management of bleeding in patients on extracorporeal membrane oxygenation: four adult case reports and a review of the literature. <i>Heart Lung</i>. 2016;45(3):232-236.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aminocaproic-acid-drug-information/abstract-text/26907195/pubmed" id="26907195" target="_blank">26907195</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Bussel.1">
<a name="Bussel.1"></a>Bussel J and Renaud T, "Disorders of Platelets," <i>Manual of Pediatric Hematology and Oncology</i>, 5th ed, Lanzkowsky P, ed, Burlington, MA: Academic Press, 2011, 372.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10617012">
<a name="10617012"></a>Casati V, Guzzon D, Oppizzi M, et al, “Hemostatic Effects of Aprotinin, Tranexamic Acid and Epsilon-Aminocaproic Acid in Primary Cardiac Surgery,” <i>Ann Thorac Surg</i>, 1999, 68(6):2252-57.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aminocaproic-acid-drug-information/abstract-text/10617012/pubmed" id="10617012" target="_blank">10617012</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6810084">
<a name="6810084"></a>Centers for Disease Control (CDC). Neonatal deaths associated with use of benzyl alcohol—United States. <i>MMWR Morb Mortal Wkly Rep</i>. 1982;31(22):290-291. <a href="https://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm" target="_blank">http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm</a>
<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aminocaproic-acid-drug-information/abstract-text/6810084/pubmed" id="6810084" target="_blank">6810084</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15073700">
<a name="15073700"></a>Chauhan S, Das SN, Bisoi A, et al, “Comparison of Epsilon Aminocaproic Acid and Tranexamic Acid in Pediatric Cardiac Surgery,” <i>J Cardiothorac Vasc Anesth</i>, 2004, 18(2):141-43.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aminocaproic-acid-drug-information/abstract-text/15073700/pubmed" id="15073700" target="_blank">15073700</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11081890">
<a name="11081890"></a>Chauhan S, Kumar BA, Rao BH, et al, "Efficacy of Aprotinin, Epsilon Aminocaproic Acid, or Combination in Cyanotic Heart Disease," <i>Ann Thorac Surg</i>, 2000, 70(4):1308-12.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aminocaproic-acid-drug-information/abstract-text/11081890/pubmed" id="11081890" target="_blank">11081890</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22556195">
<a name="22556195"></a>Connolly ES Jr, Rabinstein AA, Carhuapoma JR, et al; American Heart Association Stroke Council; Council on Cardiovascular Radiology and Intervention; Council on Cardiovascular Nursing; Council on Cardiovascular Surgery and Anesthesia; Council on Clinical Cardiology. Guidelines for the management of aneurysmal subarachnoid hemorrhage: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. <i>Stroke</i>. 2012;43(6):1711-1737.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aminocaproic-acid-drug-information/abstract-text/22556195/pubmed" id="22556195" target="_blank">22556195</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10505828">
<a name="10505828"></a>Crouch ER Jr and Crouch ER, "Management of Traumatic Hyphema: Therapeutic Options," <i>J Pediatr Ophthalmol Strabismus</i>, 1999, 36(5):238-50.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aminocaproic-acid-drug-information/abstract-text/10505828/pubmed" id="10505828" target="_blank">10505828</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9298049">
<a name="9298049"></a>Crouch ER Jr, Williams PB, Gray MK, et al, “Topical Aminocaproic Acid in the Treatment of Traumatic Hyphema,” <i>Arch Ophthalmol</i>, 1997, 115(9):1106-12.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aminocaproic-acid-drug-information/abstract-text/9298049/pubmed" id="9298049" target="_blank">9298049</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8028387">
<a name="8028387"></a>Daily PO, Lamphere JA, Dembitsky WP, et al, “Effect of Prophylactic Epsilon-Aminocaproic Acid on Blood Loss and Transfusion Requirements in Patients Undergoing First-time Coronary Artery Bypass Grafting: A Randomized, Prospective, Double-Blind Study,” <i>J Thorac Cardiovasc Surg</i>, 1994, 108(1):99-108.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aminocaproic-acid-drug-information/abstract-text/8028387/pubmed" id="8028387" target="_blank">8028387</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21773873">
<a name="21773873"></a>Diringer MN, Bleck TP, Hemphill JC 3rd, et al; Neurocritical Care Society. Critical care management of patients following aneurysmal subarachnoid hemorrhage: recommendations from the Neurocritical Care Society's Multidisciplinary Consensus Conference. <i>Neurocrit Care</i>. 2011;15(2):211-240.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aminocaproic-acid-drug-information/abstract-text/21773873/pubmed" id="21773873" target="_blank">21773873</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12891495">
<a name="12891495"></a>Downard CD, Betit P, Chang RW, et al, "Impact of AMICAR on Hemorrhagic Complications of ECMO: A Ten-Year Review," <i>J Pediatr Surg</i>, 2003, 38(8):1212-6.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aminocaproic-acid-drug-information/abstract-text/12891495/pubmed" id="12891495" target="_blank">12891495</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18349177">
<a name="18349177"></a>Eaton MP, “Antifibrinolytic Therapy in Surgery for Congenital Heart Disease,” <i>Anest Analg</i>, 2008, 106(4):1087-100.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aminocaproic-acid-drug-information/abstract-text/18349177/pubmed" id="18349177" target="_blank">18349177</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9527193">
<a name="9527193"></a>Eberle B, Mayer E, Hafner G, et al, “High-Dose Epsilon-Aminocaproic Acid Versus Aprotinin: Antifibrinolytic Efficacy in First-Time Coronary Operations,” <i>Ann Thorac Surg</i>, 1998, 65(3):667-73.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aminocaproic-acid-drug-information/abstract-text/9527193/pubmed" id="9527193" target="_blank">9527193</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18480196">
<a name="18480196"></a>Fergusson DA, Hebert PC, Mazer CD, et al, “A Comparison of Aprotinin and Lysine Analogues in High-Risk Cardiac Surgery,” <i>N Engl J Med</i>, 2008, 358(22):2319-31.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aminocaproic-acid-drug-information/abstract-text/18480196/pubmed" id="18480196" target="_blank">18480196</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11413428">
<a name="11413428"></a>Florentino-Pineda I, Blakemore LC, Thompson GH, et al, "The Effect of Epsilon-Aminocaproic Acid on Perioperative Blood Loss in Patients With Idiopathic Scoliosis Undergoing Posterior Spinal Fusion: A Preliminary Prospective Study," <i>Spine (Phila Pa 1976)</i>, 2001, 26(10):1147-51.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aminocaproic-acid-drug-information/abstract-text/11413428/pubmed" id="11413428" target="_blank">11413428</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14752343">
<a name="14752343"></a>Florentino-Pineda I, Thompson GH, Poe-Kochert C, et al, "The Effect of Amicar on Perioperative Blood Loss in Idiopathic Scoliosis: The Results of a Prospective, Randomized Double-Blind Study," <i>Spine (Phila Pa 1976)</i>, 2004, 29(3):233-8.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aminocaproic-acid-drug-information/abstract-text/14752343/pubmed" id="14752343" target="_blank">14752343</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26714677">
<a name="26714677"></a>Frontera JA, Lewin JJ 3rd, Rabinstein AA, et al; Guideline for reversal of antithrombotics in intracranial hemorrhage: a statement for healthcare professionals from the Neurocritical Care Society and Society of Critical Care Medicine. <i>Neurocrit Care</i>. 2016;24(1):6-46.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aminocaproic-acid-drug-information/abstract-text/26714677/pubmed" id="26714677" target="_blank">26714677</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6965311">
<a name="6965311"></a>Gardner FH and Helmer RE 3rd, “Aminocaproic Acid. Use in Control of Hemorrhage in Patients With Amegakaryocytic Thrombocytopenia,” <i>JAMA</i>, 1980, 243(1):35-7.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aminocaproic-acid-drug-information/abstract-text/6965311/pubmed" id="6965311" target="_blank">6965311</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Gravlee.1">
<a name="Gravlee.1"></a>Gravlee GP and Spiess B, "Pharmacologic Prophylaxis for Post-Cardiopulmonary Bypass Bleeding," <i>Cardiopulmonary Bypass: Principles and Practice</i>, 3rd ed, Philadelphia, PA: Lippincott Williams &amp; Wilkins, 2008, 522-42.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22315257">
<a name="22315257"></a>Guyatt GH, Akl EA, Crowther M, et al, “Executive Summary: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines,” <i>Chest</i>, 2012, 141(2 Suppl):7-47.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aminocaproic-acid-drug-information/abstract-text/22315257/pubmed" id="22315257" target="_blank">22315257</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27927417">
<a name="27927417"></a>Halanski MA, Cassidy JA, Hetzel S, Reischmann D, Hassan N. The efficacy of Amicar versus tranexamic acid in pediatric spinal deformity surgery: a prospective, randomized, double-blinded pilot study. <i>Spine Deform</i>. 2014;2(3):191-197.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aminocaproic-acid-drug-information/abstract-text/27927417/pubmed" id="27927417" target="_blank">27927417</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2596137">
<a name="2596137"></a>Haut MT, Mauro VF, and Davis HH, “Effect of Renal Failure and Hemodialysis on Aminocaproic Acid Plasma Concentrations,” <i>DICP</i>, 1989, 23(11):922-3.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aminocaproic-acid-drug-information/abstract-text/2596137/pubmed" id="2596137" target="_blank">2596137</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22064600">
<a name="22064600"></a>Hillis LD, Smith PK, Anderson JL, et al, “2011 ACCF/AHA Guideline for Coronary Artery Bypass Graft Surgery: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines,” <i>Circulation</i>, 2011, 124(23):2610-42.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aminocaproic-acid-drug-information/abstract-text/22064600/pubmed" id="22064600" target="_blank">22064600</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9856877">
<a name="9856877"></a>Horwitz JR, Cofer BR, Warner BW, et al, "A Multicenter Trial of 6-Aminocaproic Acid (Amicar) in the Prevention of Bleeding in Infants on ECMO," <i>J Pediatr Surg</i>, 1998, 33(11):1610-3.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aminocaproic-acid-drug-information/abstract-text/9856877/pubmed" id="9856877" target="_blank">9856877</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21904257">
<a name="21904257"></a>Hui FK, Schuette AJ, Lieber M, et al. ε-Aminocaproic acid in angiographically negative subarachnoid hemorrhage patients is safe: a retrospective review of 83 consecutive patients. <i>Neurosurgery</i>. 2012;70(3):702-705; discussion 705-706. doi:10.1227/NEU.0b013e3182358cca<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aminocaproic-acid-drug-information/abstract-text/21904257/pubmed" id="21904257" target="_blank">21904257</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20650477">
<a name="20650477"></a>Kaye JD, Smith EA, Kirsch AJ, et al, "Preliminary Experience With Epsilon Aminocaproic Acid for Treatment of Intractable Upper Tract Hematuria in Children With Hematological Disorders," <i>J Urol</i>, 2010, 184(3):1152-7.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aminocaproic-acid-drug-information/abstract-text/20650477/pubmed" id="20650477" target="_blank">20650477</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9024461">
<a name="9024461"></a>"Inactive" ingredients in pharmaceutical products: update (subject review). American Academy of Pediatrics (AAP) Committee on Drugs. <i>Pediatrics</i>. 1997;99(2):268-278.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aminocaproic-acid-drug-information/abstract-text/9024461/pubmed" id="9024461" target="_blank">9024461</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16427545">
<a name="16427545"></a>Kikura M, Levy JH, Tanaka KA, et al, “A Double-Blind, Placebo-Controlled Trial of Epsilon-Aminocaproic Acid for Reducing Blood Loss in Coronary Artery Bypass Grafting Surgery,” <i>J Am Coll Surg</i>, 2006, 202(2):216-22.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aminocaproic-acid-drug-information/abstract-text/16427545/pubmed" id="16427545" target="_blank">16427545</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27671279">
<a name="27671279"></a>Li G, Sun TW, Luo G, Zhang C. Efficacy of antifibrinolytic agents on surgical bleeding and transfusion requirements in spine surgery: a meta-analysis. <i>Eur Spine J</i>. 2017;26(1):140-154. doi:10.1007/s00586-016-4792-x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aminocaproic-acid-drug-information/abstract-text/27671279/pubmed" id="27671279" target="_blank">27671279</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Lipton.1">
<a name="Lipton.1"></a>Lipton JM, "Bone Marrow Failure," <i>Manual of Pediatric Hematology and Oncology</i>, 5th ed, Lanzkowsky P, ed, Burlington, MA: Academic Press, 2011, 131.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6782532">
<a name="6782532"></a>Lucas ON and Albert TW, “Epsilon Aminocaproic Acid in Hemophiliacs Undergoing Dental Extractions: A Concise Review,” <i>Oral Surg Oral Med Oral Pathol</i>, 1981, 51(2):115-20.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aminocaproic-acid-drug-information/abstract-text/6782532/pubmed" id="6782532" target="_blank">6782532</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9673304">
<a name="9673304"></a>Mannucci P, “Hemostatic Drugs,” <i>N Engl J Med</i>, 1998, 339(4):245-53.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aminocaproic-acid-drug-information/abstract-text/9673304/pubmed" id="9673304" target="_blank">9673304</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25641349">
<a name="25641349"></a>Marshall A, Li A, Drucker A, Dzik W. Aminocaproic acid use in hospitalized patients with hematological malignancy: a case series. <i>Hematol Oncol</i>. 2016;34(3):147-153. doi:10.1002/hon.2189<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aminocaproic-acid-drug-information/abstract-text/25641349/pubmed" id="25641349" target="_blank">25641349</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21115357">
<a name="21115357"></a>Martin K, Breuer T, Gertler R, et al, "Tranexamic Acid Versus ε-Aminocaproic Acid: Efficacy and Safety in Paediatric Cardiac Surgery," <i>Eur J Cardiothorac Surg</i>, 2011a, 39(6):892-7.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aminocaproic-acid-drug-information/abstract-text/21115357/pubmed" id="21115357" target="_blank">21115357</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21857014">
<a name="21857014"></a>Martin K, Gertler R, Liermann H, et al, "Switch From Aprotinin to ε-Aminocaproic Acid: Impact on Blood Loss, Transfusion, and Clinical Outcome in Neonates Undergoing Cardiac Surgery," <i>Br J Anaesth</i>, 2011, 107(6):934-9.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aminocaproic-acid-drug-information/abstract-text/21857014/pubmed" id="21857014" target="_blank">21857014</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6870623">
<a name="6870623"></a>McGetrick JJ, Jampol LM, Goldberg MP, et al, “Aminocaproic Acid Decreases Secondary Hemorrhage After Traumatic Hyphema,” <i>Arch Ophthalmol</i>, 1983, 101(7):1031-3.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aminocaproic-acid-drug-information/abstract-text/6870623/pubmed" id="6870623" target="_blank">6870623</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-NHF.2020">
<a name="NHF.2020"></a>National Hemophilia Foundation. MASAC document 263 - MASAC recommendations concerning products licensed for the treatment of hemophilia and other bleeding disorders. https://www.hemophilia.org/healthcare-professionals/guidelines-on-care/masac-documents/masac-document-263-masac-recommendations-concerning-products-licensed-for-the-treatment-of-hemophilia-and-other-bleeding-disorders. Updated August 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12032221">
<a name="12032221"></a>Nzerue CM and Falana B, "Refractory Hyperkalaemia Associated With Use of Epsilon-Aminocaproic Acid During Coronary Bypass in a Dialysis Patient," <i>Nephrol Dial Transplant</i>, 2002, 17(6):1150-1.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aminocaproic-acid-drug-information/abstract-text/12032221/pubmed" id="12032221" target="_blank">12032221</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17090725">
<a name="17090725"></a>Patatanian E and Fugate SE,, “Hemostatic Mouthwashes in Anticoagulated Patients Undergoing Dental Extraction,” <i>Ann Pharmacother</i>, 2006, 40(12):2205-10.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aminocaproic-acid-drug-information/abstract-text/17090725/pubmed" id="17090725" target="_blank">17090725</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7580360">
<a name="7580360"></a>Penta de Peppo A, Pierri MD, Scafuri A, et al. Intraoperative antifibrinolysis and blood-saving techniques in cardiac surgery. Prospective trial of 3 antifibrinolytic drugs. <i>Tex Heart Inst J</i>. 1995;22(3):231-236.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aminocaproic-acid-drug-information/abstract-text/7580360/pubmed" id="7580360" target="_blank">7580360</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14597516">
<a name="14597516"></a>Pieramici DJ, Goldberg MF, Melia M, et al, “A Phase III, Multicenter, Randomized, Placebo-Controlled Clinical Trial of Topical Aminocaproic Acid (Caprogel) in the Management of Traumatic Hyphema,” <i>Ophthalmology</i>, 2003, 110(11):2106-12.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aminocaproic-acid-drug-information/abstract-text/14597516/pubmed" id="14597516" target="_blank">14597516</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9635271">
<a name="9635271"></a>Pinosky ML, Kennedy DJ, Fishman RL, et al, “Tranexamic Acid Reduces Bleeding After Cardiopulmonary Bypass When Compared to Epsilon Aminocaproic Acid and Placebo,” <i>J Card Surg</i>, 1997, 12(5):330-8.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aminocaproic-acid-drug-information/abstract-text/9635271/pubmed" id="9635271" target="_blank">9635271</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33357465">
<a name="33357465"></a>Post R, Germans MR, Tjerkstra MA, et al; ULTRA Investigators. Ultra-early tranexamic acid after subarachnoid haemorrhage (ULTRA): a randomised controlled trial. <i>Lancet</i>. 2021;397(10269):112-118. doi:10.1016/S0140-6736(20)32518-6<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aminocaproic-acid-drug-information/abstract-text/33357465/pubmed" id="33357465" target="_blank">33357465</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29367334">
<a name="29367334"></a>Powers WJ, Rabinstein AA, Ackerson T, et al; American Heart Association Stroke Council. 2018 guidelines for the early management of patients with acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. <i>Stroke</i>. 2018;49(3):e46-e110. doi:10.1161/STR.0000000000000158<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aminocaproic-acid-drug-information/abstract-text/29367334/pubmed" id="29367334" target="_blank">29367334</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Manu.1">
<a name="Manu.1"></a>Refer to manufacturer's labeling.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2688504">
<a name="2688504"></a>Sane DC, Califf RM, Topol EJ, et al, " Bleeding During Thrombolytic Therapy for Acute Myocardial Infarction: Mechanisms and Management," <i>Ann Intern Med</i>, 1989, 111(12):1010-22.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aminocaproic-acid-drug-information/abstract-text/2688504/pubmed" id="2688504" target="_blank">2688504</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Singer.2021">
<a name="Singer.2021"></a>Singer RJ, Ogilvy CS, Rordorf G. Aneurysmal subarachnoid hemorrhage: treatment and prognosis. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed May 16, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8530996">
<a name="8530996"></a>Souto JC, Olover A, Zuazu-Jausoro I, et al, “Oral Surgery in Anticoagulated Patients Without Reducing the Dose of Oral Anticoagulant: A Prospective Randomized Study,” <i>J Oral Maxillofac Surg</i>, 1996, 54(1):27-32.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aminocaproic-acid-drug-information/abstract-text/8530996/pubmed" id="8530996" target="_blank">8530996</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22776238">
<a name="22776238"></a>Srivastava A, Brewer AK, Mauser-Bunschoten EP, et al; Treatment guidelines working group on behalf of The World Federation of Hemophilia. Guidelines for the management of hemophilia. <i>Haemophilia</i>. 2013;19(1):e1-47. doi:10.1111/j.1365-2516.2012.02909.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aminocaproic-acid-drug-information/abstract-text/22776238/pubmed" id="22776238" target="_blank">22776238</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18658042">
<a name="18658042"></a>Starke RM, Kim GH, Fernandez A, et al. Impact of a protocol for acute antifibrinolytic therapy on aneurysm rebleeding after subarachnoid hemorrhage. <i>Stroke</i>. 2008;39(9):2617-2621.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aminocaproic-acid-drug-information/abstract-text/18658042/pubmed" id="18658042" target="_blank">18658042</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23353035">
<a name="23353035"></a>Stricker PA, Zuppa AF, Fiadjoe JE, et al. Population pharmacokinetics of epsilon-aminocaproic acid in infants undergoing craniofacial reconstruction surgery. <i>Br J Anaesth</i>. 2013;110(5):788-799.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aminocaproic-acid-drug-information/abstract-text/23353035/pubmed" id="23353035" target="_blank">23353035</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26426230">
<a name="26426230"></a>Suarez JI. Diagnosis and management of subarachnoid hemorrhage. <i>Continuum (Minneap Minn)</i>. 2015;21(5 Neurocritical Care):1263-1287. doi:10.1212/CON.0000000000000217<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aminocaproic-acid-drug-information/abstract-text/26426230/pubmed" id="26426230" target="_blank">26426230</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9098257">
<a name="9098257"></a>Teboul BK, Jacob JL, Barsoum-Homsy M, et al, “Clinical Evaluation of Aminocaproic Acid for Managing Traumatic Hyphema in Children,” <i>Ophthalmology</i>, 1995, 102(11):1646-53.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aminocaproic-acid-drug-information/abstract-text/9098257/pubmed" id="9098257" target="_blank">9098257</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8873738">
<a name="8873738"></a>Vander Salm TJ, Kaur S, Lancey RA, et al, “Reduction of Bleeding After Heart Operations Through the Prophylactic Use of Epsilon-Aminocaproic Acid,” <i>J Thorac Cardiovasc Surg</i>, 1996, 112(4):1098-107<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aminocaproic-acid-drug-information/abstract-text/8873738/pubmed" id="8873738" target="_blank">8873738</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31929250">
<a name="31929250"></a>Verma S, Srinivas U, Sathpathy AK, Mittal P. Comparison of effectiveness of tranexamic acid and epsilon-amino-caproic-acid in decreasing postoperative bleeding in off-pump CABG surgeries: a prospective, randomized, double-blind study. <i>Ann Card Anaesth</i>. 2020;23(1):65-69. doi:10.4103/aca.ACA_142_18<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aminocaproic-acid-drug-information/abstract-text/31929250/pubmed" id="31929250" target="_blank">31929250</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12161209">
<a name="12161209"></a>Walton W, Von Hagen S, Grigorian R, et al, “Management of Traumatic Hyphema,” <i>Surv Ophthalmol</i>, 2002, 47(4):297-334.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aminocaproic-acid-drug-information/abstract-text/12161209/pubmed" id="12161209" target="_blank">12161209</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10392682">
<a name="10392682"></a>Williams GD, Bratton SL, Riley EC, et al, "Efficacy of Epsilon-Aminocaproic Acid in Children Undergoing Cardiac Surgery," <i>J Cardiothorac Vasc Anesth</i>, 1999, 13(3):304-8.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aminocaproic-acid-drug-information/abstract-text/10392682/pubmed" id="10392682" target="_blank">10392682</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8483066">
<a name="8483066"></a>Wilson JM, Bower LK, Fackler JC, et al, "Aminocaproic Acid Decreases the Incidence of Intracranial Hemorrhage and Other Hemorrhagic Complications of ECMO," <i>J Pediatr Surg</i>, 1993, 28(4):536-40.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aminocaproic-acid-drug-information/abstract-text/8483066/pubmed" id="8483066" target="_blank">8483066</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29097489">
<a name="29097489"></a>Yaghi S, Willey JZ, Cucchiara B, et al; American Heart Association Stroke Council; Council on Cardiovascular and Stroke Nursing; Council on Clinical Cardiology; and Council on Quality of Care and Outcomes Research. Treatment and outcome of hemorrhagic transformation after intravenous alteplase in acute ischemic stroke: a scientific statement for healthcare professionals from the American Heart Association/American Stroke Association. <i>Stroke</i>. 2017;48(12):e343-e361. doi:10.1161/STR.0000000000000152<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aminocaproic-acid-drug-information/abstract-text/29097489/pubmed" id="29097489" target="_blank">29097489</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23995973">
<a name="23995973"></a>Zhang YP and Trissel LA, “Stability of Aminocaproic Acid Injection Admixtures in 5% Dextrose Injection and 0.9% Sodium Chloride Injection,” <i>Int J Pharm Compound</i>, 1997, 1(2):132-4.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aminocaproic-acid-drug-information/abstract-text/23995973/pubmed" id="23995973" target="_blank">23995973</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 8561 Version 332.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
